Background Principal and secondary level of resistance to imatinib a selective receptor tyrosine kinase inhibitor (TKI) is a significant clinical issue in the control of advanced gastrointestinal Sunitinib Malate stromal tumors (GIST). amount of heterogeneity over the chosen studies. Outcomes Three randomized managed studies had been chosen for meta-analysis. Among imatinib-resistant or imatinib-intolerant sufferers 541… Continue reading Background Principal and secondary level of resistance to imatinib a selective